title: Maintenance of naive and Th1 CD4 phenotype and lack of CD8 activation in patients switching from protease inhibitors to nonnucleoside reverse transcriptase inhibitor-based antiretroviral regimens.
authors.forename: L
authors.initials: L
authors.lastname: Meroni
authors.forename: D
authors.initials: D
authors.lastname: Manganaro
authors.forename: S
authors.initials: S
authors.lastname: Varchetta
authors.forename: N
authors.initials: N
authors.lastname: Gatti
authors.forename: A
authors.initials: A
authors.lastname: Riva
authors.forename: A D
authors.initials: AD
authors.lastname: Monforte
authors.forename: M
authors.initials: M
authors.lastname: Galli
mesh_terms: D036541:ADP-ribosyl Cyclase; D051997:ADP-ribosyl Cyclase 1; D019380:Anti-HIV Agents / Q000627:therapeutic use*; D015703:Antigens, CD; D000943:Antigens, Differentiation / Q000032:analysis; D023241:Antiretroviral Therapy, Highly Active; D015496:CD4-Positive T-Lymphocytes; D018414:CD8-Positive T-Lymphocytes; D019040:E-Selectin / Q000032:analysis; D015658:HIV Infections / Q000188:drug therapy* / Q000276:immunology; D015497:HIV-1; D006801:Humans; D017493:Leukocyte Common Antigens / Q000032:analysis; D008213:Lymphocyte Activation; D008562:Membrane Glycoproteins; D009244:NAD+ Nucleosidase / Q000032:analysis; D012367:RNA, Viral / Q000032:analysis; D018894:Reverse Transcriptase Inhibitors / Q000627:therapeutic use*
chemical_list: D019380:Anti-HIV Agents; D015703:Antigens, CD; D000943:Antigens, Differentiation; D019040:E-Selectin; D008562:Membrane Glycoproteins; D012367:RNA, Viral; D018894:Reverse Transcriptase Inhibitors; D017493:Leukocyte Common Antigens; D036541:ADP-ribosyl Cyclase; C498154:CD38 protein, human; D009244:NAD+ Nucleosidase; D051997:ADP-ribosyl Cyclase 1